Nadim Ahmed is CEO & President at Cullinan Therapeutics, Inc. (CGEM). They have made 11 open-market trades across 1 company since 2022, most recently 2026-02-24.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $100K since 2022, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CGEM | 390,803 | $8.0M |
| CELG | 40,694 | $4.4M |
| BMY | 46,549 | $3.0M |
| Total | $15.4M |
Shares reported on the most recent Form 4, priced at the 2026-02-25 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CGEM | SELL | 2026-02-24 | 2026-02-25 | $14.47 | $196K | +6.8% | -10.4% | +7.9% |
| CGEM | SELL | 2026-02-20 | 2026-02-23 | $13.62 | $223K | +11.1% | +0.0% | +10.1% |
| CGEM | SELL | 2025-12-23 | 2025-12-29 | $10.01 | $199K | +8.6% | +18.0% | +33.7% |
| CGEM | SELL | 2025-02-25 | 2025-02-27 | $8.53 | $214K | +0.2% | -12.5% | -9.4% |
| CGEM | SELL | 2024-12-24 | 2024-12-27 | $11.87 | $100K | -4.8% | -12.3% | -29.4% |
| CGEM | SELL | 2023-12-26 | 2023-12-27 | $9.24 | $39K | +7.2% | +30.6% | +67.6% |
| CGEM | SELL | 2023-06-28 | 2023-06-29 | $11.40 | $9K | -6.4% | -4.4% | -8.5% |
| CGEM | SELL | 2023-05-23 | 2023-05-24 | $9.15 | $6K | +33.9% | +35.3% | +20.6% |
| CGEM | SELL | 2023-04-25 | 2023-04-26 | $10.59 | $8K | -5.1% | +0.3% | +2.3% |
| CGEM | SELL | 2023-03-23 | 2023-03-27 | $10.51 | $7K | -7.6% | -7.9% | +4.5% |
| CGEM | BUY | 2022-06-06 | 2022-06-07 | $12.40 | $100K | -9.0% | +2.5% | -5.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.